Results 191 to 200 of about 253,625 (250)
Impact of radium-223 on bone imaging and biochemical markers with and without bone-modifying agents in bone-metastatic castration-resistant prostate cancer: results from the kyucog-1901 study. [PDF]
Eur J Nucl Med Mol ImagingShiota M +14 more
europepmc +1 more source
Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model. [PDF]
Int J Mol Sci, 2023 Suominen MI +10 more
europepmc +1 more source
Joint Regional Uptake Quantification of Thorium-227 and Radium-223 Using a Multiple-Energy-Window Projection-Domain Quantitative SPECT Method. [PDF]
IEEE Trans Med ImagingLi Z +5 more
europepmc +1 more source
EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer [PDF]
European Journal of Nuclear Medicine and Molecular Imaging, 2017 Radium Ra-223 dichloride (radium-223, Xofigo®) is a targeted alpha therapy approved for the treatment of castration-resistant prostate cancer (CRPC) with symptomatic bone metastases and no known visceral metastatic disease.
Thorsten D Poeppel +2 more
exaly +2 more sources
Chemotherapy following radium‐223 dichloride treatment in ALSYMPCA [PDF]
Prostate, 2016 BACKGROUND Radium-223 prolongs overall survival in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases, regardless of prior docetaxel.
Oliver Sartor +2 more
exaly +2 more sources